Target intelligence / Profile preview

Cyclin-dependent kinase 6 messenger RNA 3' untranslated region (CDK6 mRNA 3' UTR) (CDK6 mRNA 3' UTR)

Target
CDK6 mRNA 3' UTR
Molecular classification
RNA, Untranslated region, Non-coding RNA region
01

Overview

The Cyclin-dependent kinase 6 (CDK6) messenger RNA 3' untranslated region (3' UTR) is a critical regulatory segment of the CDK6 transcript that governs post-transcriptional gene expression [6, 15]. This region is exceptionally long and contains numerous binding sites for microRNAs (miRNAs) and RNA-binding proteins, which collectively modulate mRNA stability and translational efficiency [1, 18]. In many cancers, such as leukemias, breast cancer, and bladder cancer, the CDK6 3' UTR is a site of significant dysregulation; for instance, alternative polyadenylation can lead to 3' UTR shortening, which removes tumor-suppressive miRNA binding sites and results in the pathological overexpression of the CDK6 protein [2, 8]. Therapeutic strategies targeting this region primarily involve the use of miRNA mimics, such as miR-29 and miR-124, to restore translational repression and induce cell cycle arrest [4, 13]. Additionally, research is exploring small molecules and antisense oligonucleotides that can interact with the secondary structures of the 3' UTR to downregulate CDK6 expression, offering a potential alternative to direct protein kinase inhibitors [5, 9].

Other names
CDK6 3'-UTRCyclin-dependent kinase 6 3' untranslated regionCDK6 3-prime UTRCDK6 mRNA 3-UTR
02

Mechanism of action

miRNA-mediated translational repression and mRNA degradation through sequence-specific binding to the 3' UTR

03

Biological functions

Regulation of gene expressionmRNA stabilityTranslation regulationCell cycle regulationPost-transcriptional modification
04

Disease associations

CancerLeukemiaBreast cancerProstate cancerBladder cancerCervical cancerMyelofibrosis
05

Safety considerations

Off-target effects on other mRNAs sharing seed sequencesChallenges in systemic delivery of RNA-based therapeuticsPotential for unintended immune activation by exogenous RNASystemic toxicity of lipid nanoparticle delivery systems
06

Interacting drugs

miR-29 mimic

6 more in the full profile.

07

Biomarkers

CDK6 mRNA expression levelsmiR-29 expression levelsmiR-124 expression levels3' UTR length (alternative polyadenylation status)rs8179 single nucleotide polymorphismrs42033 single nucleotide polymorphism

Beyond the preview

Go deeper on Cyclin-dependent kinase 6 messenger RNA 3' untranslated region (CDK6 mRNA 3' UTR) (CDK6 mRNA 3' UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin-dependent kinase 6 messenger RNA 3' untranslated region (CDK6 mRNA 3' UTR) (CDK6 mRNA 3' UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call